{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:25:11Z","timestamp":1792401911213,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T00:00:00Z","timestamp":1358380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s40256-012-0002-3","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T10:51:55Z","timestamp":1358333515000},"page":"37-46","source":"Crossref","is-referenced-by-count":131,"title":["Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies"],"prefix":"10.1007","volume":"13","author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene A.","family":"Braeckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Stirtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh N.","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,17]]},"reference":[{"issue":"2","key":"2_CR1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1253\/circj.CJ-09-0706","volume":"74","author":"P Libby","year":"2010","unstructured":"Libby P, Okamoto Y, Rocha VZ, et al. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74(2):213\u201320.","journal-title":"Circ J"},{"key":"2_CR2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jacl.2011.07.005","volume":"5","author":"MH Davidson","year":"2011","unstructured":"Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338\u201367.","journal-title":"J Clin Lipidol"},{"issue":"12","key":"2_CR3","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1161\/01.CIR.96.12.4219","volume":"96","author":"SJ Hwang","year":"1997","unstructured":"Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96(12):4219\u201325.","journal-title":"Circulation"},{"issue":"1","key":"2_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1734-1140(09)70004-0","volume":"61","author":"C Lawson","year":"2009","unstructured":"Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61(1):22\u201332.","journal-title":"Pharmacol Rep"},{"issue":"1","key":"2_CR5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/ars.2009.2733","volume":"13","author":"I Levitan","year":"2010","unstructured":"Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal. 2010;13(1):39\u201375.","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"2_CR6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.104.529297","volume":"112","author":"C Meisinger","year":"2005","unstructured":"Meisinger C, Baumert J, Khuseyinova N, et al. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005;112(5):651\u20137.","journal-title":"Circulation"},{"issue":"3","key":"2_CR7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1586\/erc.10.18","volume":"8","author":"PP Toth","year":"2010","unstructured":"Toth PP, McCullough PA, Wegner MS, et al. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. Expert Rev Cardiovasc Ther. 2010;8(3):425\u201338.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"12A","key":"2_CR8","doi-asserted-by":"crossref","first-page":"41F","DOI":"10.1016\/j.amjcard.2008.04.018","volume":"101","author":"MA Corson","year":"2008","unstructured":"Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008;101(12A):41F\u201350F.","journal-title":"Am J Cardiol"},{"issue":"2","key":"2_CR9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1160\/TH09-05-0297","volume":"102","author":"H Schuett","year":"2009","unstructured":"Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215\u201322.","journal-title":"Thromb Haemost"},{"key":"2_CR10","doi-asserted-by":"crossref","unstructured":"Nystrom T. C-reactive protein: a marker or a player? Clin Sci (Lond) 2007;113(2):79\u201381.","DOI":"10.1042\/CS20070121"},{"issue":"25","key":"2_CR11","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jacc.2011.02.038","volume":"57","author":"HE Bays","year":"2011","unstructured":"Bays HE. Adiposopathy is \u201csick fat\u201d a cardiovascular disease? J Am Coll Cardiol. 2011;57(25):2461\u201373.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2_CR12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","volume":"109","author":"CM Ballantyne","year":"2004","unstructured":"Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837\u201342.","journal-title":"Circulation"},{"issue":"21","key":"2_CR13","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1001\/archinte.165.21.2479","volume":"165","author":"CM Ballantyne","year":"2005","unstructured":"Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165(21):2479\u201384.","journal-title":"Arch Intern Med"},{"issue":"6A","key":"2_CR14","doi-asserted-by":"crossref","first-page":"35C","DOI":"10.1016\/j.amjcard.2006.11.020","volume":"99","author":"HE Bays","year":"2007","unstructured":"Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99(6A):35C\u201343C.","journal-title":"Am J Cardiol"},{"key":"2_CR15","first-page":"245","volume-title":"The Johns Hopkins textbook of dyslipidemia","author":"H Bays","year":"2010","unstructured":"Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO, editor. The Johns Hopkins textbook of dyslipidemia. Philadelphia: Lippincott Williams & Wolters Kluwer; 2010. p. 245\u201357."},{"issue":"5","key":"2_CR16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","volume":"108","author":"HE Bays","year":"2011","unstructured":"Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682\u201390.","journal-title":"Am J Cardiol"},{"issue":"7","key":"2_CR17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","volume":"110","author":"CM Ballantyne","year":"2012","unstructured":"Ballantyne CM, Bays HE, Kastelein JJ, et al. A phase 3, multicenter, placebo-controlled, randomized, double-blind, 12-week study to evaluate the effect of two doses of AMR101 on fasting serum triglycerides and other lipid parameters in statin-treated patients with persistent high triglycerides (\u2265200 and <500\u00a0mg\/dL): the ANCHOR study. Am J Cardiol. 2012;110(7):984\u201392.","journal-title":"Am J Cardiol"},{"issue":"26","key":"2_CR18","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","volume":"344","author":"PM Ridker","year":"2001","unstructured":"Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959\u201365.","journal-title":"N Engl J Med"},{"issue":"21","key":"2_CR19","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"3","key":"2_CR20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1017\/S0007114508921723","volume":"100","author":"L Garrido-Sanchez","year":"2008","unstructured":"Garrido-Sanchez L, Garcia-Fuentes E, Rojo-Martinez G, et al. Inverse relation between levels of anti-oxidized-LDL antibodies and eicosapentanoic acid (EPA). Br J Nutr. 2008;100(3):585\u20139.","journal-title":"Br J Nutr"},{"issue":"2","key":"2_CR21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.atherosclerosis.2004.04.004","volume":"175","author":"MD Mesa","year":"2004","unstructured":"Mesa MD, Buckley R, Minihane AM, et al. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein. Atherosclerosis. 2004;175(2):333\u201343.","journal-title":"Atherosclerosis"},{"issue":"4","key":"2_CR22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1542-474X.2011.00465.x","volume":"16","author":"E Watanabe","year":"2011","unstructured":"Watanabe E, Sobue Y, Sano K, et al. Eicosapentaenoic acid for the prevention of recurrent atrial fibrillation. Ann Noninvasive Electrocardiol. 2011;16(4):373\u20138.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"7","key":"2_CR23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0891-5849(03)00407-6","volume":"35","author":"TA Mori","year":"2003","unstructured":"Mori TA, Woodman RJ, Burke V, et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med. 2003;35(7):772\u201381.","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"2_CR24","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/hr.2009.145","volume":"32","author":"N Satoh","year":"2009","unstructured":"Satoh N, Shimatsu A, Kotani K, et al. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res. 2009;32(11):1004\u20138.","journal-title":"Hypertens Res"},{"issue":"1","key":"2_CR25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2337\/dc06-1179","volume":"30","author":"N Satoh","year":"2007","unstructured":"Satoh N, Shimatsu A, Kotani K, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care. 2007;30(1):144\u20136.","journal-title":"Diabetes Care"},{"issue":"3","key":"2_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3945\/jn.108.100354","volume":"139","author":"DS Kelley","year":"2009","unstructured":"Kelley DS, Siegel D, Fedor DM, et al. DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr. 2009;139(3):495\u2013501.","journal-title":"J Nutr"},{"issue":"9","key":"2_CR27","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/ejcn.2009.20","volume":"63","author":"MA Micallef","year":"2009","unstructured":"Micallef MA, Munro IA, Garg ML. An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals. Eur J Clin Nutr. 2009;63(9):1154\u20136.","journal-title":"Eur J Clin Nutr"},{"key":"2_CR28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1476-511X-8-36","volume":"8","author":"RJ Bloomer","year":"2009","unstructured":"Bloomer RJ, Larson DE, Fisher-Wellman KH, et al. Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study. Lipids Health Dis. 2009;8:36.","journal-title":"Lipids Health Dis"},{"issue":"6 Pt 1","key":"2_CR29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/clinchem\/48.6.877","volume":"48","author":"DC Chan","year":"2002","unstructured":"Chan DC, Watts GF, Barrett PH, et al. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48(6 Pt 1):877\u201383.","journal-title":"Clin Chem"},{"issue":"2","key":"2_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3945\/ajcn.110.003871","volume":"93","author":"AC Skulas-Ray","year":"2011","unstructured":"Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr. 2011;93(2):243\u201352.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"2_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00394-008-0758-z","volume":"48","author":"MW Pedersen","year":"2009","unstructured":"Pedersen MW, Koenig W, Christensen JH, et al. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr. 2009;48(1):1\u20135.","journal-title":"Eur J Nutr"},{"issue":"3","key":"2_CR32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00394-010-0126-7","volume":"50","author":"TL Nelson","year":"2011","unstructured":"Nelson TL, Hokanson JE, Hickey MS. Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females. Eur J Nutr. 2011;50(3):185\u201393.","journal-title":"Eur J Nutr"},{"issue":"5","key":"2_CR33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacl.2009.08.001","volume":"3","author":"MH Davidson","year":"2009","unstructured":"Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3 ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009;3(5):332\u201340.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2_CR34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","volume":"104","author":"CK Glass","year":"2001","unstructured":"Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104(4):503\u201316.","journal-title":"Cell"},{"issue":"3","key":"2_CR35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","volume":"6","author":"HE Bays","year":"2008","unstructured":"Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391\u2013409.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"2_CR36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1358\/dot.2008.44.3.1166387","volume":"44","author":"H Bays","year":"2008","unstructured":"Bays H. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. Drugs Today (Barc). 2008;44(3):205\u201346.","journal-title":"Drugs Today (Barc)"},{"issue":"9567","key":"2_CR37","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090\u20138.","journal-title":"Lancet"},{"issue":"2","key":"2_CR38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.5876","volume":"18","author":"H Itakura","year":"2011","unstructured":"Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99\u2013107.","journal-title":"J Atheroscler Thromb"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-012-0002-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-012-0002-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-012-0002-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T13:28:06Z","timestamp":1595251686000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-012-0002-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,17]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["2"],"URL":"https:\/\/doi.org\/10.1007\/s40256-012-0002-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,17]]}}}